-
公开(公告)号:US11279739B2
公开(公告)日:2022-03-22
申请号:US16386885
申请日:2019-04-17
摘要: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
-
公开(公告)号:US20210236663A1
公开(公告)日:2021-08-05
申请号:US17125905
申请日:2020-12-17
发明人: Longbin Liu , Matthew Lee , Celia Dominguez , Peter David Johnson , Christopher John Brown , Sarah Hayes , Adrian Kotey , Matthew Robert Mills , Michael Edward Prime
IPC分类号: A61K51/04 , C07D401/14 , C07D401/06 , C07D471/04 , C07D401/12 , C07D491/107 , C07D487/04 , C07D413/14 , C07B59/00
摘要: Provided herein are certain compounds and imaging agents useful for detecting a condition or disorder associated with protein aggregation, compositions thereof, and methods of their use.
-
公开(公告)号:US11059836B2
公开(公告)日:2021-07-13
申请号:US16530594
申请日:2019-08-02
发明人: Celia Dominguez , Samuel Coe , Peter David Johnson , Michael Edward Prime , Christopher John Brown , Sébastien René Gabriel Galan , Paul Richard Giles , Jonathan Bard , Elise Luciennen Paulette Gadouleau , Thomas Martin Krülle , Daniel Clark-Frew , John Wityak , Alex Kiselyov , Sarah Hayes
IPC分类号: C07D513/04 , C07D413/14 , C07D417/04 , A61K51/04 , C07D413/12 , C07D263/57 , C07D498/04 , C07D405/14 , C07D413/04 , C07D471/04
摘要: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
-
公开(公告)号:US20210060187A1
公开(公告)日:2021-03-04
申请号:US16987277
申请日:2020-08-06
发明人: Celia Dominguez , John Wityak , Jonathan Bard , Christopher John Brown , Michael Edward Prime , Peter David Johnson , Thomas Martin Krulle , Daniel Clark-Frew , Duane Higgins , Matthew Robert Mills , Richard Waldron Marston , Samuel Coe , Samantha Brown , Sarah Hayes
IPC分类号: A61K51/04 , C07D513/04 , C07D487/04 , C07D513/14 , C07B59/00
摘要: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
-
公开(公告)号:US10065948B2
公开(公告)日:2018-09-04
申请号:US15315713
申请日:2015-06-01
发明人: Celia Dominguez , Ignacio Muñoz-Sanjuán , Roland W. Bürli , Christopher A. Luckhurst , Daniel R. Allen , Gilles Raphy , Perla Breccia , Alan F. Haughan , Grant Wishart , Samantha J. Hughes , Rebecca E. Jarvis , Huw D. Vater , Stephen D. Penrose , Michael Wall , Andrew J. Stott , Elizabeth A. Saville-Stones
IPC分类号: C07D417/04 , C07D231/54 , C07D401/04 , C07D403/04 , C07D231/56 , C07D239/88 , C07D277/60 , C07D239/70 , C07C259/08
CPC分类号: C07D417/04 , C07C259/08 , C07D231/54 , C07D231/56 , C07D239/70 , C07D239/74 , C07D239/88 , C07D275/04 , C07D277/60 , C07D401/04 , C07D403/04
摘要: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
-
公开(公告)号:US10047073B2
公开(公告)日:2018-08-14
申请号:US15148884
申请日:2016-05-06
发明人: Michel C. Maillard , Perla Breccia , Celia Dominguez , Alan F. Haughan , Rebecca E. Jarvis , Christopher A. Luckhurst , Elizabeth A. Saville-Stones , Andrew J. Stott , Amanda Van de Poël , Michael Wall , Grant Wishart
IPC分类号: C07D413/12 , C07D491/107
摘要: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
-
7.
公开(公告)号:US09938252B2
公开(公告)日:2018-04-10
申请号:US14392307
申请日:2014-09-23
IPC分类号: C07D327/06 , C07D215/06 , C07D235/26 , C07D263/58 , C07D307/79 , C07D311/04 , C07D317/50 , C07D311/02 , C07D317/46 , C07D317/62 , C07D319/18 , C07D233/70 , C07D263/38 , C07D211/72 , C07D319/16
CPC分类号: C07D327/06 , C07D211/72 , C07D215/06 , C07D233/70 , C07D235/26 , C07D263/38 , C07D263/58 , C07D307/79 , C07D311/02 , C07D311/04 , C07D317/46 , C07D317/50 , C07D317/62 , C07D319/16 , C07D319/18
摘要: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described; which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
公开(公告)号:US20170305900A1
公开(公告)日:2017-10-26
申请号:US15482327
申请日:2017-04-07
发明人: Celia Dominguez , Ignacio Muñoz-Sanjuán , Michel Maillard , Christopher A. Luckhurst , Rebecca E. Jarvis , Roland W. Bürli , Daniel R. Allen , Alan F. Haughan , Perla Breccia , Huw D. Vater , Andrew J. Stott , Stephen D. Penrose , Michael Wall , Elizabeth A. Saville-Stones , Grant Wishart , Samantha J. Hughes
IPC分类号: C07D471/04 , C07D277/64 , C07C259/08 , C07D277/62 , C07D275/04 , C07D261/20 , C07D241/42 , C07D241/12 , C07D239/26 , C07D231/56 , C07D231/12 , C07D213/64 , C07D213/61 , C07D213/56 , C07D333/60 , C07C2601/02 , C07C2601/10
CPC分类号: C07D471/04 , C07C259/08 , C07C2601/02 , C07C2601/10 , C07D213/56 , C07D213/61 , C07D213/64 , C07D231/12 , C07D231/56 , C07D239/26 , C07D241/12 , C07D241/42 , C07D261/20 , C07D275/04 , C07D277/62 , C07D277/64 , C07D333/60
摘要: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
-
公开(公告)号:US20170224684A1
公开(公告)日:2017-08-10
申请号:US15411535
申请日:2017-01-20
发明人: Celia Dominguez , Vahri Beaumont , Ignacio Muñoz-Sanjuán , Roland W. Bürli , Alan F. Haughan , Christopher A. Luckhurst , Michael Wall , Gilles Raphy , Beth Thomas
IPC分类号: A61K31/505
CPC分类号: A61K31/505 , C07D239/26
摘要: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
-
10.
公开(公告)号:US09649310B2
公开(公告)日:2017-05-16
申请号:US15042964
申请日:2016-02-12
发明人: Celia Dominguez , Leticia M. Toledo-Sherman , Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson
IPC分类号: A61K31/506 , A61K31/505 , A61K31/5377 , A61K31/513
CPC分类号: A61K31/506 , A61K31/505 , A61K31/513 , A61K31/5377 , C07D239/26 , C07D239/28 , C07D239/42 , C07D401/04 , C07D403/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D491/044 , C07D491/048 , C07D491/052
摘要: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
-
-
-
-
-
-
-
-